The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Innovative Bispecific Antibody Therapies in Cancer Treatment Emerge as Patent Filings SurgeDublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Bispecific Antibody & Cancer Patent Landscape Analysis" report ...

The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 ...

Hence, they are classified as locally-advanced, surgically unresectable (stage III ... of patients with histologically-proven pancreatic ductal adenocarcinoma at this point in time is 19.6 ...

Wells Fargo (NYSE:WFC) initiated coverage on Merus N.V. (NASDAQ:MRUS), currently trading at $41.54 with a market capitalization of $2.84 billion, with an Overweight rating and a price target of $91.00 ...

Pancreatic cancer can cause back pain that spreads from the abdomen. It often affects the middle of the back and may feel like a dull ache. For some people, the pain may come and go. Pancreatic ...

published results of the registrational phase 2 eNRGy trial for Bizengri ® (zenocutuzumab), the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung ...

Zenocutuzumab helps fill an important need for patients with advanced pancreatic cancer and NSCLC with NRG1 gene fusions, said Alison Schram M.D., ...

published results of the registrational phase 2 eNRGy trial for Bizengri ® (zenocutuzumab), the first and only treatment indicated for adults with pancreatic adenocarcinoma or non-small cell lung ...

Pancreatic Ductal Carcinoma Market Outlook 2025-2035: The pancreatic ductal carcinoma market is demonstrating a promising trajectory, with a projected CAGR of 5.83% across the 7 major markets between ...